Search results for "Relationship"

showing 10 items of 3616 documents

Clonidine induces nitric oxide- and prostaglandin-mediated vasodilation in healthy human skin

2005

Sustained sympathetic activation not only leads to vasoconstriction but also might induce paradox vasodilation. This study was performed to explore whether and how alpha(2)-receptor stimulation mediates this vasodilation. We investigated 11 healthy subjects in 33 dermal microdialysis (MD) sessions. After nerve trunk blockade, MD fibers were inserted and perfused with physiological saline until skin trauma-related vasodilation subsided. Thereafter, fibers were perfused with either clonidine solutions (10(-3), 5 x 10(-4), 10(-4) mol/l), N(G)-monomethyl-l-arginine (L-NMMA; nitric oxide synthase blocker), acetylsalicylic acid (ASA; cyclooxygenase blocker), or combinations of these. Laser-Dopple…

AdultMalemedicine.medical_specialtySympathetic nervous systemPhysiologyImidazoline receptorProstaglandinVasodilationStimulationNitric OxideClonidineNitric oxidechemistry.chemical_compoundReference ValuesSkin Physiological PhenomenaPhysiology (medical)Internal medicineAdrenergic alpha-2 Receptor AgonistsmedicineHumansSkinDose-Response Relationship DrugChemistryVasodilationEndocrinologymedicine.anatomical_structureEicosanoidProstaglandinsmedicine.symptomAdrenergic alpha-AgonistsBlood Flow VelocityVasoconstrictionJournal of Applied Physiology
researchProduct

Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.

2004

Abstract Triflusal is an antiplatelet drug related to aspirin, with different pharmacological properties and a lower haemorrhagic risk. We aimed at comparing their effects on platelet and endothelial activation in type 2 diabetes mellitus (T2DM). In a randomized, double-blind, parallel group study, we compared the effects of three daily regimens (300, 600, and 900mg) of triflusal, and aspirin (100mg/day) on urinary 11-dehydro-thromboxane (TX)B 2 , index of in vivo platelet activation, ex vivo platelet function using the analyzer PFA-100, plasma von Willebrand factor (vWF), P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and serum nitrite a…

AdultMalemedicine.medical_specialtyThromboxaneaspirinRadioimmunoassaychemistry.chemical_compoundThromboxane A2Von Willebrand factorDouble-Blind MethodInternal medicinetype 2 diabetes triellitusvon Willebrand Factormedicineplatelet activationHumansPlateletPlatelet activationAgedRetrospective StudiesAspirinbiologyDose-Response Relationship DrugMiddle AgedSalicylatesThromboxane B2Thromboxane B2triflusalP-SelectinEndocrinologychemistryDiabetes Mellitus Type 2biology.proteinTriflusalFemaleCardiology and Cardiovascular MedicineBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFollow-Up Studies
researchProduct

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.

2006

BACKGROUND The efficacy of consensus interferon (CIFN), a synthetic IFN with optimised in vitro activity, was assessed in chronic hepatitis C virus (HCV) patients who had failed the pretreatment with interferon-alpha (IFNalpha) and ribavirin. METHODS One hundred and three patients after non-response (n=69) or relapse (n=34) to IFNalpha+/-ribavirin were randomly assigned to high-dose induction (CIFN 27-->9 microg daily for 24 weeks, 9 microg t.i.w. for 24 weeks) or low-dose treatment (CIFN 18 microg t.i.w. for 12 weeks, 9 microg t.i.w. for 36 weeks); each with ribavirin 800 mg/day. Follow-up was 24 weeks. RESULTS Non-responder patients treated with high-dose induction had higher early virolo…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentConsensus interferonAlpha interferonHepacivirusGastroenterologyAntiviral AgentsVirusVirological responsechemistry.chemical_compoundChronic hepatitisInternal medicineRibavirinMedicineHumansIn patientDosingProspective StudiesAgedHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis C ChronicMiddle AgedViral Loaddigestive system diseasesTreatment OutcomechemistryResearch DesignImmunologyFemaleInterferonsbusinessBiomarkersFollow-Up StudiesLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks

2011

Guidelines recommend that patients with chronic hepatitis C virus (HCV) infection be treated with pegylated interferon and ribavirin for 24, 48, or 72 weeks, based on their virologic response to treatment. We investigated the effects of treating patients for individualized durations.We treated 398 treatment-naïve patients who had HCV genotype 1 infections with pegylated interferon alfa-2b and ribavirin for 24, 30, 36, 42, 48, 60, or 72 weeks (mean of 39 weeks, termed individualized therapy); the duration of therapy was determined based on baseline viral load and the time point at which HCV RNA levels became undetectable (measured at weeks 4, 6, 8, 12, 24, and 30). Results were compared with…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentGenotypeTranscription-mediated amplificationHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyVirusPolyethylene GlycolsYoung AdultLiver diseasechemistry.chemical_compoundPegylated interferonGermanyInternal medicineRibavirinHumansMedicinePrecision MedicineAgedDose-Response Relationship DrugHepatologybusiness.industryStandard treatmentRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesClinical trialTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy CombinationFemalebusinessViral loadmedicine.drugGastroenterology
researchProduct

Effect of Cabergoline on Metabolism in Prolactinomas.

2013

<b><i>Introduction:</i></b> Hyperprolactinemia has been implicated in the pathogenesis of obesity and glucose intolerance and is reportedly associated with an impaired metabolic profile. The current study aimed at investigating the effects of 12- and 60-month treatment with cabergoline (CAB) on metabolic syndrome (MetS) in patients with prolactinomas. <b><i>Patients and Methods:</i></b> 61 patients with prolactinomas (13 men, 48 women, 41 with microadenoma, 20 with macroadenoma), aged 34.4 ± 10.3 years, entered the study. In all patients, prolactin (PRL) and metabolic parameters were assessed at diagnosis and after 12 and 60 months of continuo…

AdultMalemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismTreatment outcomeprolactinomasAntineoplastic AgentsSettore MED/13 - EndocrinologiaPathogenesisCellular and Molecular NeuroscienceEndocrinologyInsulin resistanceMetabolic DiseasesCabergolineInternal medicinePrevalenceMedicineHumansInsulinPituitary NeoplasmsProspective StudiesErgolinesAdiposityMetabolic SyndromeDose-Response Relationship DrugEndocrine and Autonomic Systemsbusiness.industryPituitary tumorsMetabolismFastingmedicine.diseasePrognosisProlactinProlactinHyperprolactinemiaEndocrinologyTreatment OutcomeprolactinomacabergolineFemaleMetabolic syndromeInsulin Resistancebusinessmetabolismmedicine.drug
researchProduct

Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria pati…

2002

Background: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU). Methods: Twenty patients with CU were studied. They were selected on the basis of double-blind placebo-controlled challenge (DBPC) with acetyl salicylic acid (ASA) and food additives. Ten patients (group B) were negative to both challenges. Ten patients (group C) presented urticaria and/or the appearance of angioedema during or 24 h after challenge, with reactions to ASA (five patients) or food additives (fiv…

AdultMalemedicine.medical_specialtyTime FactorsUrticariaUrinary systemImmunologyMethylhistamineProvocation testAdministration OralUrinePlaceboGastroenterologyBronchoconstrictor AgentsDrug HypersensitivityExcretionchemistry.chemical_compoundDouble-Blind MethodSodium BenzoateInternal medicineSodium GlutamatemedicineHumansSulfitesImmunology and AllergyCyclooxygenase InhibitorsTartrazineLeukotriene E4CreatinineAspirinDose-Response Relationship DrugAngioedemabusiness.industryMethylhistaminesMiddle AgedEndocrinologyItalychemistryChronic DiseaseFemaleFood AdditivesControlled Clinical Trials as Topicmedicine.symptombusinessBiomarkersAllergy
researchProduct

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol

2006

Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a prostacyclin analogue, used, according to a new protocol, in patients with Raynaud’s phenomenon secondary to Systemic Sclerosis. Methods: in this randomized study we treated 30 patients with Iloprost given by intravenous infusion, at progressively increasing doses (starting from 0.5 ng/Kg/min up 2 ng/Kg/min) over a period of 6 hours a day for ten days in two consecutive weeks, with repeated cycles at regular intervals of three months for 18 months. The results were compared with those obtained in 30 other patients, who had received the same drug but with different posologic schemes. Results: …

AdultMalemedicine.medical_specialtyTime FactorsVasodilator AgentsSeverity of Illness IndexDrug Administration ScheduleSclerodermalaw.inventionRheumatologyRandomized controlled trialQuality of lifelawSeverity of illnessmedicineHumansPharmacology (medical)IloprostProspective StudiesDosingInfusions IntravenousProspective cohort studySystemic Sclerosis Raynaud's phenomenon Iloprost Quality of lifeScleroderma SystemicDose-Response Relationship DrugVascular diseasebusiness.industryRaynaud DiseaseMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaQuality of LifeFemalebusinessIloprostmedicine.drugRheumatology
researchProduct

Psychological Conflicts Between Relatives During the Long-Term Course After Successful Living Organ Donation

2008

The German transplantation law prefers living organ donation between close relatives and spouses, which is assumed to guarantee unequivocal altruistic motivation. Since 2001, 68 recipient-donor-pairs, who aspired to have a renal or liver transplantation, underwent a systematic psychosomatic evaluation. Meanwhile, 43 transplantations were performed including 34 renal and 9 liver cases. Seventeen recipient-donor-pairs were readministered evaluations by the department of psychosomatic medicine after 1 to 6 years after transplantation for long-term follow-up. In 10 cases of medically successful transplantation, we identified severe conflicts between donor, recipient, and next-of-kin. Major conf…

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentFamily conflictStalemateLiver transplantationNephrectomyConflict PsychologicalInterviews as TopicInterpersonal relationshipLiving organ donationLiving DonorsmedicineHepatectomyHumansFamilyInterpersonal RelationsOrgan donationSpousesTransplantationbusiness.industryPsychosomatic medicineMiddle AgedSurgeryTransplantationFamily medicineFemaleSurgerybusinessFollow-Up StudiesTransplantation Proceedings
researchProduct

A proposal for an anonymous living organ donation in Germany.

2003

Abstract In Germany, living organ donation of paired and usually not regenerating organs is restricted by law to related individuals, as well as persons who ‘obviously entertain an especially intimate personal relationship'. When this law was adopted in 1997, the intention of the legislator was to guarantee the free will of the donor and to exclude any trade of organs. Since then the transplantation of cadaveric organs has not increased. Additional organs were donated from living donors. However, for a number of reasons only a limited array of transplantation centers use living organ donation as a supply facing a steadily increasing number of patients with chronic renal failure. Living orga…

AdultMalemedicine.medical_specialtyTissue and Organ ProcurementLife qualityOrgan transplantationPathology and Forensic MedicineABO Blood-Group SystemTherapeutic approachLiving organ donationGermanyLiving DonorsMedicineHumansIntensive care medicineKidney transplantationbusiness.industryPersonal relationshipMiddle Agedmedicine.diseaseAltruismKidney TransplantationSurgeryTransplantationIssues ethics and legal aspectsBlood Group IncompatibilityChronic renal failurebusinessLegal medicine (Tokyo, Japan)
researchProduct

Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study.

2011

The aim of this study was to verify the efficacy and the safety of transtympanic dexamethasone to treat sudden sensorineural hearing loss as first and single drug method. Considering ethical implication of performing a mininvasive procedure on middle ear, we matched such proposed treatment with systemic prednisone administration that represents the widest adopted protocol. Randomized prospective study was conducted. The inclusion criterion was a sudden sensorineural hearing loss of at least 30 dB across three contiguous frequencies over a period of 24 h. Group A received transtympanic steroid injections; Group B received oral administration of steroids. 25 patients were treated with transty…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss SensorineuralAdministration OralInjections IntralesionalRisk AssessmentSeverity of Illness IndexDexamethasoneDrug Administration ScheduleAudiometryOral administrationPrednisoneSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedAnalysis of Variancemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryGeneral MedicineHearing Loss SuddenMiddle AgedSurgeryCochlea Deafness Round window Sudden sensorineural hearing loss Steroid TranstympanicTreatment OutcomeOtorhinolaryngologyOtorhinolaryngologyFemaleNeurosurgeryAudiometrybusinessmedicine.drugFollow-Up Studies
researchProduct